主权项 |
1. A method for determining lung cancer disease progression or for pathological stratification of solitary indeterminate nodules detected during lung cancer screening or for determining the likelihood of disease progression in a subject, the method comprising:
obtaining a biological sample from the subject; assaying a level in the biological sample of a biomarker in a panel of biomarkers, the panel comprising at least one biomarker selected from the group consisting of Epidermal growth factor (EGF), Angiopoietin-2, granulocyte colony-stimulating factor (G-CSF), bone morphogenic protein 9 (BMP-9), Endoglin, Endothelin-1, Leptin, fibroblast growth factor-1 (FGF-1), FGF-2, Follistatin, interleukin-8 (IL-8), hepatocyte growth factor (HGF), heparin-binding epidermal growth factor (HB-EGF), placental growth factor (PLGF), vascular endothelial growth factor-A (VEGF-A), VEGF-C and VEGF-D; comparing the biomarker level in the subject's sample to a cutoff value for each biomarker measured for the panel of biomarkers; and determining whether the biomarker level is above or below the cutoff value. |